A ground-breaking technology that could revolutionise gene therapy, particularly for numerous genetic eye illnesses, has been licenced by the Indian Institute of Technology (IIT), Kanpur to Reliance Life Sciences Pvt. Ltd.
"Gene therapy" involves replacing the dysfunctional gene with a functional copy of the gene. For the first time, a technology associated with gene therapy has been created and given to a business in India by a university. Reliance Life Sciences will continue to develop the IIT Kanpur-developed gene therapy technology as an indigenous product.
The patented technology which was developed by Prof. Jayandharan Giridhara Rao and Shubham Maurya from the Department of Biological Sciences and Bioengineering (BSBE), IIT Kanpur, alters an organism's gene to remedy a hereditary illness, IIT Kanpur stated in a media release.
"IIT Kanpur is committed to developing impactful technologies in the field of healthcare, and we are delighted to see the licensing of this gene therapy technology to Reliance Life Sciences," said Prof. Abhay Karandikar, Director of IIT Kanpur.
“We are pleased to have the opportunity to work with IIT Kanpur to further develop this important technology, Reliance Life Sciences is a research-driven, medical biotechnology company and we are thrilled to collaborate and take forward this innovative technology to commercialisation," said K. V. Subramaniam, President of Reliance Life Sciences.
At an MoU exchange event on March 10, the formal signing of the technology licence agreement between IIT Kanpur and Reliance Life Sciences Pvt. Ltd. took place in front of various dignitaries, including Prof. Abhay Karandikar (Director, IIT Kanpur), and K. V. Subramaniam (Licensee & President of Reliance Life Sciences). Prof. Ankush Sharma (PIC, Innovation & Incubation), Prof. Amitabha Bandyopadhyay (Head, BSBE Department), Prof. Jayandharan Giridhara Rao (Dept. of BSBE) of IIT Kanpur, and Praveen Sharma (General Manager) of Reliance Life Sciences were also in attendance.
Disclaimer: Reliance Life Sciences is a part of the Promoter Group of Reliance Industries Limited. Moneycontrol is a part of the Network18 group. Network18 is controlled by Independent Media Trust, of which Reliance Industries is the sole beneficiary.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
